Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 10/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 4/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673331 | 0.90 | GPR88 (0.60) | GPR88ACACB | |
| SCHEMBL1673330 | 0.90 | GPR88 (0.60) | GPR88ACACB | |
| SCHEMBL20425203 | 0.88 | GPR88 (0.44) | GPR88 | |
| SCHEMBL16805949 | 0.88 | GAA (0.46) | GPR88CYP1A2GAACYP2C9CYP2C19 | |
| SCHEMBL30280584 | 0.87 | CHRNA7 (0.48) | MEN1CYP1A2CYP3A4GAACYP2D6 | |
| SCHEMBL15229037 | 0.87 | ALDH1A1 (0.48) | GPR88 | |
| SCHEMBL1554164 | 0.86 | GPR88 (0.64) | GPR88 | |
| SCHEMBL2503502 | 0.86 | GPR88 (0.64) | GPR88 | |
| SCHEMBL17625015 | 0.86 | GPR88 (0.56) | GPR88CNR2RIPK1 | |
| SCHEMBL14044935 | 0.86 | GPR88 (0.56) | GPR88CNR2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002448-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4404935-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| EP-4404934-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023049060-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | disclosed |
| WO-2023049058-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368109-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | GPR88 106/4885MEN1 4877/4885CYP1A2 1832/4885 |
| US-20250002448-A1 | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRM1, CHRM5 | GPR88 82/4885MEN1 4874/4885CYP1A2 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.